Research programme : antibody therapeutics - xCella Biosciences

Drug Profile

Research programme : antibody therapeutics - xCella Biosciences

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator xCella Biosciences
  • Class Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 30 May 2017 Early research in Undefined indication in USA
  • 30 May 2017 xCella Biosciences in-licenses OmniAb® technology from Ligand Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top